デフォルト表紙
市場調査レポート
商品コード
956262

世界の癌バイオマーカー市場規模調査:プロファイリングテクノロジー別、生体分子別、癌タイプ別、用途別、および地域別予測:2020年~2027年

Global Cancer Biomarkers Market Size study, by Profiling Technology, by Biomolecule, by Cancer Type, by Application and Regional Forecasts 2020-2027

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
世界の癌バイオマーカー市場規模調査:プロファイリングテクノロジー別、生体分子別、癌タイプ別、用途別、および地域別予測:2020年~2027年
出版日: 2020年08月28日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の癌バイオマーカーの市場規模は、2019年に約109億米ドルとなりました。同市場は、予測期間の2020~2027年で11.8%を超える健全な成長率で成長すると予測されています。

世界保健機関(WHO)によると、癌は世界で2番目の主要な死因であり、2018年には先進国と途上国における死亡者数の70%近くを占めています。癌のバイオマーカーは、人体における癌性細胞の存在を示す追跡可能な分子または物質です。バイオマーカーは腫瘍によって覆われた分子/物質、または癌細胞の存在に対する人体の特有の反応を示す場合があります。個別の診断技術を使用していくつかの癌バイオマーカーを検査することによる癌の予防と診断は、迅速な治療成果を上げるための重要なアプローチです。プロテオミクス、遺伝学、糖鎖生物学、およびエピジェネティクスは、癌の診断、疫学、予後診断に広く使用できる主要なバイオマーカーです。癌患者数の増加、癌治療に対する患者の意識の高まり、および癌バイオマーカーの開発に対する投資と政府資金の増加は、予測期間中の市場を劇的に成長させうる要因となります。

International Agency for Research on Cancer (IARC)によると、2018年の世界の新規癌症例数はおよそ1,810万件、癌による死亡は960万件と報告されています。また、世界の癌罹患率は、2040年までに新規症例数が2,750万件、癌による死亡が1,630万件に増加すると予測されています。これにより、世界的に癌バイオマーカーの需要が高まると見込まれます。ただし、ワクチン開発コストの高さ、政府による規制と償還政策の不備は、2020年から2027年の予測期間における市場の成長を妨げる要因となっています。

当レポートでは、世界の癌バイオマーカー市場について調査し、市場の概要とともに、プロファイリングテクノロジー別、生体分子別、癌タイプ別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の癌バイオマーカー市場の定義と範囲

第3章 世界の癌バイオマーカー市場力学

  • 癌バイオマーカー市場の影響分析(2018-2027)

第4章 世界の癌バイオマーカー市場:業界分析

  • ポーターの5フォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの提言と結論

第5章 プロファイリングテクノロジー別世界の癌バイオマーカー市場

  • 市場のスナップショット
  • プロファイリングテクノロジー別世界の癌バイオマーカー市場、パフォーマンス-潜在的な分析
  • プロファイリングテクノロジー別世界の癌バイオマーカー市場の見積と予測:2017-2027年測(10億米ドル)
  • 癌バイオマーカー市場、サブセグメント分析
    • オミクステクノロジー
    • イメージングテクノロジー
    • 免疫学的検査
    • 細胞遺伝学検査

第6章 生体分子別世界の癌バイオマーカー市場

  • 市場のスナップショット
  • 生体分子別世界の癌バイオマーカー市場、パフォーマンス-潜在的な分析
  • 生体分子別世界の癌バイオマーカー市場の見積と予測:2017-2027年測(10億米ドル)
  • 癌バイオマーカー市場、サブセグメント分析
    • 遺伝的バイオマーカー
    • タンパク質バイオマーカー
    • 糖鎖バイオマーカー

第7章 癌タイプ別世界の癌バイオマーカー市場

  • 市場のスナップショット
  • 癌タイプ別世界の癌バイオマーカー市場、パフォーマンス-潜在的な分析
  • 癌タイプ別世界の癌バイオマーカー市場の見積と予測:2017-2027年測(10億米ドル)
  • 癌バイオマーカー市場、サブセグメント分析
    • 乳癌
    • 肺癌
    • 大腸癌
    • 前立腺癌
    • 胃癌
    • その他

第8章 用途別世界の癌のバイオマーカー市場

  • 市場のスナップショット
  • 用途別世界の癌のバイオマーカー市場、パフォーマンス-潜在的な分析
  • 用途別世界の癌のバイオマーカー市場の見積と予測:2017-2027年測(10億米ドル)
  • 癌バイオマーカー市場、サブセグメント分析
    • 診断
    • 創薬と開発
    • 予後
    • リスクアセスメント
    • その他

第9章 世界の癌バイオマーカー市場、地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他

第10章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • Bristol-Myers Squibb Company
    • Exact Sciences Corporation
    • F.Hoffmann-La Roche Ltd.
    • Merck KGaA
    • PerkinElmer, Inc.
    • Qiagen N.V.
    • Siemens AG
    • Thermo Fisher Scientific, Inc

第11章 調査プロセス

図表

LIST OF FIGURES

  • FIG 1. Global Cancer Biomarkers market, research methodology
  • FIG 2. Global Cancer Biomarkers market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Cancer Biomarkers market, key trends 2019
  • FIG 5. Global Cancer Biomarkers market, growth prospects 2020-2027
  • FIG 6. Global Cancer Biomarkers market, porters 5 force model
  • FIG 7. Global Cancer Biomarkers market, pest analysis
  • FIG 8. Global Cancer Biomarkers market, value chain analysis
  • FIG 9. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 10. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 11. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 12. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 13. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 14. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 15. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 16. Global Cancer Biomarkers market by segment, 2017 & 2027 (USD Billion)
  • FIG 17. Global Cancer Biomarkers market, regional snapshot 2017 & 2027
  • FIG 18. North America Cancer Biomarkers market 2017 & 2027 (USD Billion)
  • FIG 19. Europe Cancer Biomarkers market 2017 & 2027 (USD Billion)
  • FIG 20. Asia-Pacific Cancer Biomarkers market 2017 & 2027 (USD Billion)
  • FIG 21. Latin America Cancer Biomarkers market 2017 & 2027 (USD Billion)
  • FIG 22. Global Cancer Biomarkers market, company market share analysis (2019)
目次

Title:
Global Cancer Biomarkers Market Size study, by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics-based Tests), by Biomolecule (Genetic Biomarkers, Protein Biomarkers, Glyco-biomarkers), by Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others), by Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others) and Regional Forecasts 2020-2027.

Global Cancer Biomarkers Market is valued at approximately at USD 10.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 11.8% over the forecast period 2020-2027. According to the World Health Organization (WHO), cancer is the second major cause of death around the world and is responsible for nearly 70% of deaths occurred in the developed and developing countries in 2018. A cancer biomarker is the traceable molecule or substance that demonstrates the existence of cancerous cells in the human body. A biomarker may be a molecule/substance covered by a tumor or a specific response of the human body to the existence of cancerous cells. The prevention & diagnosis of cancer by examining several cancer biomarkers through the use of distinct diagnostic techniques is a profound approach to attain rapid results for treatment. Proteomic, genetic, glycomic, and epigenetic are the major biomarkers that can be extensively used for cancer diagnosis, epidemiology and prognosis. An increase in the number of cancer patients, growing awareness among patients towards cancer therapy, and rising investment and government funding in the development of cancer biomarkers are the few factors responsible for the impressive growth of the market during the forecast period. According to the International Agency for Research on Cancer (IARC), there were approximately 18.1 million novel cases of cancer and 9.6 million cancer deaths were reported throughout the world in 2018. Also, the global prevalence of cancer is projected to grow to around 27.5 million new cancer cases and nearly 16.3 million cancer deaths by the year 2040. This, in turn, is likely to strengthen the demand for Cancer Biomarkers, globally. However, the high development cost of vaccine and unregulated government regulations and reimbursement policies are the few factors impeding the market growth over the forecast period of 2020-2027.

The regional analysis of the global Cancer Biomarkers market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising usage of cancer biomarkers in drug discovery and development, along with the large presence of market players in the region. Whereas Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rise in prevalence of cancer and improving healthcare infrastructure in the developing nations, such as China and India, are the few factors creating a lucrative opportunity for the growth of the cancer vaccine market in the Asia-Pacific region.

Major market player included in this report are:

Abbott Laboratories

Bio-Rad Laboratories, Inc.

Bristol-Myers Squibb Company

Exact Sciences Corporation

F.Hoffmann-La Roche Ltd.

Merck KGaA

PerkinElmer, Inc.

Qiagen N.V.

Siemens AG

Thermo Fisher Scientific, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Profiling Technology:

Omic Technologies

Imaging Technologies

Immunoassays

Cytogenetics-based Tests

By Biomolecule:

Genetic Biomarkers

Protein Biomarkers

Glyco-biomarkers

By Cancer Type:

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Others

By Application:

Diagnostics

Drug Discovery and Development

Prognostics

Risk Assessment

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Cancer Biomarkers Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Cancer Biomarkers Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Cancer Biomarkers Market, by Profiling Technology, 2018-2027 (USD Billion)
    • 1.2.3. Cancer Biomarkers Market, by Biomolecule, 2018-2027 (USD Billion)
    • 1.2.4. Cancer Biomarkers Market, by Cancer Type, 2018-2027 (USD Billion)
    • 1.2.5. Cancer Biomarkers Market, by Application, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cancer Biomarkers Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cancer Biomarkers Market Dynamics

  • 3.1. Cancer Biomarkers Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Cancer Biomarkers Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Cancer Biomarkers Market, by Profiling Technology

  • 5.1. Market Snapshot
  • 5.2. Global Cancer Biomarkers Market by Profiling Technology, Performance - Potential Analysis
  • 5.3. Global Cancer Biomarkers Market Estimates & Forecasts by Profiling Technology 2017-2027 (USD Billion)
  • 5.4. Cancer Biomarkers Market, Sub Segment Analysis
    • 5.4.1. Omic Technologies
    • 5.4.2. Imaging Technologies
    • 5.4.3. Immunoassays
    • 5.4.4. Cytogenetics-based Tests

Chapter 6. Global Cancer Biomarkers Market, by Biomolecule

  • 6.1. Market Snapshot
  • 6.2. Global Cancer Biomarkers Market by Biomolecule, Performance - Potential Analysis
  • 6.3. Global Cancer Biomarkers Market Estimates & Forecasts by Biomolecule 2017-2027 (USD Billion)
  • 6.4. Cancer Biomarkers Market, Sub Segment Analysis
    • 6.4.1. Genetic Biomarkers
    • 6.4.2. Protein Biomarkers
    • 6.4.3. Glyco-biomarkers

Chapter 7. Global Cancer Biomarkers Market, by Cancer Type

  • 7.1. Market Snapshot
  • 7.2. Global Cancer Biomarkers Market by Cancer Type, Performance - Potential Analysis
  • 7.3. Global Cancer Biomarkers Market Estimates & Forecasts by Cancer Type 2017-2027 (USD Billion)
  • 7.4. Cancer Biomarkers Market, Sub Segment Analysis
    • 7.4.1. Breast Cancer
    • 7.4.2. Lung Cancer
    • 7.4.3. Colorectal Cancer
    • 7.4.4. Prostate Cancer
    • 7.4.5. Stomach Cancer
    • 7.4.6. Others

Chapter 8. Global Cancer Biomarkers Market, by Application

  • 8.1. Market Snapshot
  • 8.2. Global Cancer Biomarkers Market by Application - Potential Analysis
  • 8.3. Global Cancer Biomarkers Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
  • 8.4. Cancer Biomarkers Market, Sub Segment Analysis
    • 8.4.1. Diagnostics
    • 8.4.2. Drug Discovery and Development
    • 8.4.3. Prognostics
    • 8.4.4. Risk Assessment
    • 8.4.5. Others

Chapter 9. Global Cancer Biomarkers Market, Regional Analysis

  • 9.1. Cancer Biomarkers Market, Regional Market Snapshot
  • 9.2. North America Cancer Biomarkers Market
    • 9.2.1. U.S. Cancer Biomarkers Market
      • 9.2.1.1. Profiling Technology breakdown estimates & forecasts, 2017-2027
      • 9.2.1.2. Biomolecule breakdown estimates & forecasts, 2017-2027
      • 9.2.1.3. Cancer Type breakdown estimates & forecasts, 2017-2027
      • 9.2.1.4. Application breakdown estimates & forecasts, 2017-2027
    • 9.2.2. Canada Cancer Biomarkers Market
  • 9.3. Europe Cancer Biomarkers Market Snapshot
    • 9.3.1. U.K. Cancer Biomarkers Market
    • 9.3.2. Germany Cancer Biomarkers Market
    • 9.3.3. France Cancer Biomarkers Market
    • 9.3.4. Spain Cancer Biomarkers Market
    • 9.3.5. Italy Cancer Biomarkers Market
    • 9.3.6. Rest of Europe Cancer Biomarkers Market
  • 9.4. Asia-Pacific Cancer Biomarkers Market Snapshot
    • 9.4.1. China Cancer Biomarkers Market
    • 9.4.2. India Cancer Biomarkers Market
    • 9.4.3. Japan Cancer Biomarkers Market
    • 9.4.4. Australia Cancer Biomarkers Market
    • 9.4.5. South Korea Cancer Biomarkers Market
    • 9.4.6. Rest of Asia Pacific Cancer Biomarkers Market
  • 9.5. Latin America Cancer Biomarkers Market Snapshot
    • 9.5.1. Brazil Cancer Biomarkers Market
    • 9.5.2. Mexico Cancer Biomarkers Market
  • 9.6. Rest of The World Cancer Biomarkers Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Abbott Laboratories
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Bio-Rad Laboratories, Inc.
    • 10.2.3. Bristol-Myers Squibb Company
    • 10.2.4. Exact Sciences Corporation
    • 10.2.5. F.Hoffmann-La Roche Ltd.
    • 10.2.6. Merck KGaA
    • 10.2.7. PerkinElmer, Inc.
    • 10.2.8. Qiagen N.V.
    • 10.2.9. Siemens AG
    • 10.2.10. Thermo Fisher Scientific, Inc

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption